|
|
Volumn 73, Issue 16, 2013, Pages 4988-4991
|
|
The 19th annual prostate cancer foundation scientific retreat
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABIRATERONE ACETATE;
ANTIANDROGEN;
ANTINEOPLASTIC AGENT;
ARN 509;
ATN 291;
ATN 658;
BICALUTAMIDE;
CLR 1501;
DIAPEUTICS;
ETHISTERONE;
HEAT SHOCK PROTEIN 27;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY J591;
MONOCYTE CHEMOTACTIC PROTEIN 1;
OGX 427;
PHOSPHOLIPID DERIVATIVE;
PYRVINIUM EMBONATE;
SCATTER FACTOR;
STROMAL CELL DERIVED FACTOR 1;
SULFORAPHANE;
TETRAHYDROPYRVINIUM;
TRACER;
TRANSFERRIN;
TRANSFORMING GROWTH FACTOR BETA;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
UROKINASE;
UROKINASE RECEPTOR;
WNT PROTEIN;
ZIRCONIUM 89;
ZIRCONIUM DERIVATIVE;
ANTINEOPLASTIC ACTIVITY;
CANCER GROWTH;
CANCER PROGNOSIS;
CASTRATION RESISTANT PROSTATE CANCER;
CONFERENCE PAPER;
DISEASE RESISTANCE;
DRUG BINDING SITE;
DRUG PROTEIN BINDING;
DRUG RECEPTOR BINDING;
DRUG TARGETING;
EPITHELIUM CELL;
HUMAN;
MOLECULAR IMAGING;
NONHUMAN;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PLASTICITY;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
PROSTATE CANCER;
SIGNAL TRANSDUCTION;
THREAT;
TUMOR MICROENVIRONMENT;
WELLBEING;
WORKSHOP;
|
|
EID: 84882726614
PISSN: 00085472
EISSN: 15387445
Source Type: Journal
DOI: 10.1158/0008-5472.CAN-12-4576 Document Type: Conference Paper |
|
Times cited : (7)
|
|
References (0)
|
